Fosfomycin I.v. for Treatment of Severely Infected Patients

Who May Qualify: - Male or female patients aged ≥ 18 years - Treatment with fosfomycin according to the (national) Summary of Product Characteristics (SmPC) of fosfomycin i.v. - Patients with osteomyelitis, complicated urinary tract infection, nosocomial lower respiratory tract infection, bacterial meningitis/central nervous system infection, bacteraemia/sepsis, skin and soft tissue infection, endocarditis or other infection, each as far as covered by the respective nationally relevant SmPC - Written willing to sign a consent form of the participant (or person in charge in case of patients incapable of giving consent) Who Should NOT Join This Trial: - Previous documentation of the patient in the present study - Patients participating in an interventional clinical trial - Patients with known hypersensitivity to fosfomycin or any of the excipients - Terminally ill patients - Patients with "do not resuscitate order" - Palliative treatment approach - Failure of \> 3 of the following organ systems: respiratory system, nervous system, cardiovascular system, liver, coagulation, kidney - Manifest Human weakened immune system Virus (HIV) disease (Acquired weakened immune system Syndrome, AIDS) - Fosfomycin treatment as 4th line treatment or at later stage - Patients with involvement of fungi or mycobacteria in the targeted infection Always talk to your doctor about whether this trial is right for you.